Pharmaceutical

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.

Jan 23, 2024 - 18:00
Genentech signs nanoparticle deal worth up to $644m with GenEdit
Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.
Read the original article

Tags:

Previous Article

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Next Article

Sanofi signs agreement to acquire Inhibrx for $1.7bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How the CEO of the largest medical device accelerator molds medtech startups

STAT+: How the CEO of the largest medical device accele...

Nov 21, 2023

Community health workers, experts in the in-between, fight for their place in the system

Community health workers, experts in the in-between, fi...

Aug 7, 2023

STAT+: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution

STAT+: Doudna institute hatches plan to ‘cure hundreds ...

Jan 10, 2024